Radioactive iron is taken up with high specificity by the erythropoietic bone marrow 1 and will irradiate the neighboring abnormal cells supposed to be homogeneously disFor many hematological malignancies, high-dose chemoradiotherapy followed by bone marrow transtributed among the erythropoietic precursors. We have used high doses of the short-lived positron emitter 52 Fe, 2 in plantation offers the best and sometimes the only chance for cure. However, the main causes of failure of this addition to the conditioning regimen before bone marrow transplantation. Twenty-four patients were evaluated in a therapy are relapse and toxicity. In order to selectively deliver higher doses of radiotherapy to the bone marphase II study. row and to spare normal organs, we explored 52 Fe therapy before a conventional BMT conditioning regimen. Twenty-four patients at high risk for relapse after BMT Patients and methods were included in a phase II study. The median followup was 42 months. The median 
Fe. The patients recovered hematopo-
a physical half-life of 8.2 h and decays mainly by positron iesis without toxicity in excess of that expected with conemission (high energy ␤ + particles). Its daughter product, ventional conditioning alone. The 3-year DFS prob- Mn, the Keywords: 52 Fe; radiotherapy; bone marrow transplanmaximum energy of its ␤ + particles is 2.6 Mev, with a tation maximum radial range in tissue of 0.40 cm and a maximum path length of 1.30 cm. The main physical properties are shown in Table 1 . The 511-keV gamma rays from positron annihilation A major limitation of bone marrow transplantation is the allow for imaging and quantitative evaluation of the distriinability of classical preparative regimens to eradicate the bution of the radionuclide. A whole body dual-head rectidisease without causing extramedullary toxicities. Hence linear scanner fitted with a coincidence detection unit was for most hematologic malignancies, recurrence of the used to delineate the bone marrow and liver areas underlying disease remains the most important cause of ( Figure 1 ) and to obtain a quantitative evaluation of the 52 Fe treatment failure after marrow transplantation, despite the uptakes. The uptakes in the bone marrow and the liver were use of maximum tolerated doses of systemic therapy.
expressed as percentages of total scan activity localized in Although hematologic malignancies show steep dosethe bone marrow and in the liver. 3 In normal human subresponse curves to irradiation, it has been difficult to take advantage of this because of the toxicities to non-hematopoietic tissues, mainly the lungs, the liver and the gastrointestinal tract. In patients with diseases largely confined to Mn decayed at the site of On day −7, a quantitative scintigraphy using the whole their uptake and that a steady state existed from day −9 to body dual-head rectilinear scanner was performed and day −7. allowed for imaging and quantitative evaluation of the distribution of the radionuclide. As soon as the radiation- Fe to the bone dose was adjusted so as not to deliver more than 500 rad marrow, to the liver and to the whole body were calculated and 1200 rad from 52 Fe to the liver and the bone using the plasma iron clearance, the transfer rate constants marrow, respectively.
of iron from plasma to bone marrow and liver, the surface One day later, the conditioning regimen was started; the counting data over bone marrow and liver, the fraction of day of bone marrow transplantation was day 0.
injected radioiron reaching bone marrow and liver, and the injected 52 Fe dose. In the radiation dose calculation, the source organs were the BM and the liver. The target organs Ferrokinetics were the BM, the liver and the whole body. The RAD from Mn to the bone marrow, the A three-compartment model, including peripheral blood, liver and the whole body were calculated according to the bone marrow and liver was used to calculate the transfer method described in MIRD pamphlet no. 1: 
Patients
This study started in October 1990 and included a total of 24 patients as of 1 December 1994. Updated results were analyzed as of 30 September 1995, with a median followup time of 42 months (range 9-61 months). There were 13 men and 11 women with a median age of 39 years (range 17-53 years).
Clinical data on these patients are given in Table 2 . Diseases included acute myeloid leukemia, (n = 8), acute lymphoblastic leukemia (n = 4), multiple myeloma (n = 4), myelodysplastic syndrome (n = 3), chronic myeloid leukemia (n = 3), non-Hodgkin's lymphoma (n = 1) and congenital hemoglobinopathy (n = 1). ALL = acute lymphoblastic leukemia; MM = multiple myeloma; AML = acute myeloblastic leukemia; MDS = myelodysplastic syndrome; NHL = nonHodgkin's lymphoma; CML = chronic myeloid leukemia; Hbp = hemoglobinopathy; CR1 = first complete remission; PD = progressive disease; R = refractory disease; HTB = high tumor burden; AP = acute phase; ABMT = autograft; PBSC = peripheral blood stem cell transplantation; BMT = allograft; SIB = sibling donor HLA identical; UNR = unrelated donor; SIB H = haploidentical; Cy = cyclophosphamide (120 mg/kg); Ara-C = cytosine arabinoside (1 g/m2/12 h, for 2 days); Mel = melphalan (140 mg/m 2 ); Bus = busulfan (16 mg/kg); TBI = total body irradiation (800 rad or 1000 rad, single dose); EPO = erythropoietin (daily dose 150 U/kg subcutaneously, three times weekly for 3 weeks); Survival, + means alive. ability of relapse after bone marrow transplantation because Results of either disease characteristics (high tumor burden, ALL Ph+) or disease status at the time of transplantation Ferrokinetics and radiation-absorbed doses (progressive or refractory disease, second remission). (2) The values of the transfer rate constants (k) and the radiProbability of satisfactory iron uptake in the marrow, as ation-absorbed doses are shown in Tables 3 and 4 . The predicted by the iron clearance, the plasma iron and the median 52 Fe dose was 59 mCi (range 32-85 mCi). The transferrin saturation. 4 (3) The production of 52 Fe and the median uptake in the marrow was 77% (range 36-90%) availability of a transplant bed.
with a median RAD of 626 rad (range 151-1144 rad). For Five patients had an autologous bone marrow transplant the liver, the median uptake was 21.5% (range 10-64%), and 19 an allogeneic bone marrow transplant (17 sibling, resulting in a median RAD of 338 rad (range 82-797 rad). two unrelated donors). The conditioning regimens were
The median whole body RAD was 47.6 rad (range 22-based on cyclophosphamide and TBI, except in two patients 70 rad). (congenital hemoglobinopathy and second allograft for multiple myeloma, one each) in whom busulfan-cyclophosphamide was used.
Toxicity GVHD prophylaxis consisted of cyclosporin A (CsA)-methotrexate (MTX), CsA-anti-IL2 receptor MoAb and There were no immediate untoward side-effects after the injection of radioiron. Hematopoietic recovery was not CsA-MTX-anti-IL2 receptor MoAb in eight, six and five patients respectively. Prophylaxis against veno-occlusive delayed: the median times to reach 1 × 10 9 WBC/l, 0.5 × 10 9 neutrophils/l, 25 × 10 9 and 100 × 10 9 platelets/l disease of the liver (VOD) included heparin and/or prostaglandin E1.
were 18 days (11-43), 19 days (11-56), 23 days (13-not achieved) and 57 days (25-not achieved), respectively. Five patients with hypocellular bone marrow, a hemoglobin below normal and low reticulocyte count, received However, five patients presented prolonged thrombocytopenia concomitant with GVHD, sepsis, relapse or VOD. recombinant erythropoietin at a daily dose of 150 U/kg, subcutaneously, three times weekly, for a total of 3 weeks
No excess in occurrence of GVHD, either acute (14/19) or chronic (5/19), could be observed. Two patients developed before the start of conditioning. The treatment protocol has been accepted by the Ethics Committee of the Medical VOD. The first patient suffered from congenital hemoglobinopathy with secondary hemochromatosis (patient 12) and School of the University. C Jacquy et al 194 Table 3 Transfer rate constants (k)
Outcome
The 3-year survival probability was 46% (95% CI: 25-kBM kblood kliver 68% were still alive at the time of evaluation (nos 18 and 19). 13  387  797  48  44  56  14  446  82  26  89  11  15  626  715  58  56  44  16  151  394  22  36  64  17  605  183  38  84  16  18  822  215  50  85  15  19  1036  319  65  84  16  20  530  636  50  56  44  21  627  235  41  81  19  22  462  498  42  58  42  23  1092  365  70  83  17  24  487  161  38  67  33 RAD = radiation-absorbed dose (expression in rad); UM = marrow uptake; UL = liver uptake.
received cyclophosphamide and busulfan as conditioning regimen. The RAD to the liver in this case was 530 rad; the estimated RAD to the liver was of only 183 rad. 
